Skip to Main Content

Everyone loves a winner, but who are they? Let us help you figure it out. Each Friday, we will provide a quick rundown of individuals or companies that accomplished something worth noting. But to be fair, we will also point out those who, well, had a rough time. And if you have a nomination, send us a note. We would not want anyone to feel left out, even the losers.


Drug makers: The Securities and Exchange Commission told 10 big drug companies they won’t face enforcement actions if they exclude shareholder resolutions to require justifications for price hikes and the risks these may pose to stockholders. The proposals were filed last fall by a coalition of 300 institutional investors. Donna Meyer of Mercy Investment Services decried what she called “active obstruction.” She has a point. But the refusal is not surprising. The pharmaceutical industry has also fought state bills that were introduced to cull the same information. So much for transparency, though.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!